<DOC>
	<DOCNO>NCT01034631</DOCNO>
	<brief_summary>The purpose study determine whether BNC105P combination with/following everolimus effective treatment progressive metastatic clear cell renal cell carcinoma follow prior tyrosine kinase inhibitor .</brief_summary>
	<brief_title>BNC105P Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Phase I : Patients accrue classic 3 patient per dose per cohort design , 21-day cycle - Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2 - Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2 - Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2 - Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2 Phase II : Patients randomize 1:1 Arm A Arm B Combination Arm A : Everolimus 10 mg + BNC105P MTD ( Phase 1 study ) 21 day cycle Sequential Arm B : Everolimus 10 mg 21 day cycle - Patients receive BNC105P monotherapy 16 mg/m2 follow progression intolerable toxicity everolimus therapy . Karnofsky Performance Score ( KPS ) ≥70 within 7 day prior registration protocol therapy . Life Expectancy : Not specify Hematopoietic : - White blood cell count ( WBC ) &gt; 3.5 K/mm3 - Hemoglobin ( Hgb ) &gt; 8.5 g/dL - Platelets &gt; 100 K/mm3 - Absolute neutrophil count ( ANC ) &gt; 1.5 K/mm3 Hepatic : - Total Bilirubin &lt; 1.25 x ULN - Aminotransferase ( AST ALT ) &lt; 2.5 x ULN Renal : - Serum Creatinine &lt; 2.5 x ULN ( upper limit normal ) Cardiovascular : - No significant cardiovascular event within 6 month ( CVA , CAD , peripheral arterial obstruction , arrhythmia , cardiac dysfunction ) registration protocol therapy - No history clinical CHF LVEF &lt; 50 % Echo ( MUGA ) within 30 day prior registration protocol therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological cytological proof component ( percent ) clear cell RCC ( renal cell carcinoma ) . Metastatic locally advance unresectable RCC . NOTE : Prior nephrectomy mandatory . Progressive disease 12 prior VEGFdirected tyrosine kinase inhibitor ( TKIs ) . Measurable disease accord RECIST obtain image within 30 day prior registration protocol therapy . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 4 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior registration protocol therapy . No active brain metastasis . Patients neurological symptom must undergo head CT scan brain MRI exclude brain metastasis within 30 day prior registration protocol therapy . NOTE : A patient prior brain metastasis eligible complete radiation treatment brain metastasis ≥30 day prior registration protocol therapy , steroid , asymptomatic . No currently active malignancy . No treatment investigational agent within 14 day prior registration protocol therapy . NOTE : If treat investigational agent within 14 day prior registration , AE must resolve back baseline . Prior cancer treatment must complete least 14 day prior registration protocol therapy patient must recover acute toxic effect regimen . With exception Bevacizumab treatment , must complete 30 day prior registration protocol therapy . Prior radiation therapy &lt; 25 % bone marrow [ see bone marrow radiation chart study procedure manual ( SPM ) ] allow complete within 30 day prior registration protocol therapy . Corrected QT interval ( QTc ) ≤ 450 msec least 7 day prior registration protocol therapy . No clinically significant infection judge treat investigator . No liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . No collect duct , medullary sarcomatoid histology . No prior treatment temsirolimus everolimus phase II component study . NOTE : Prior treatment agent permit phase I component study . No use full dose , therapeutic anticoagulation warfarin related anticoagulant unfractionated low molecular weight heparin . No uncontrolled hypertension ( BP &gt; 150/100mmHg despite full dos 1 antihypertensive medication ) . No thrombotic event within 6 month ( deep vein thrombosis , pulmonary embolism ) registration protocol therapy . No grade 2 great peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Kidney Cancer</keyword>
	<keyword>BNC105P</keyword>
</DOC>